One-carbon Therapeutics

Executive Summary

One-Carbon Therapeutics is a Swedish pre-clinical biotechnology company pioneering a novel approach to treating difficult cancers, inflammation, and autoimmune diseases by targeting the disease-specific one-carbon metabolism pathway. This pathway is integral to the DNA damage response (DDR), and the company's small molecule inhibitors aim to selectively disrupt the aberrant metabolic dependencies of diseased cells while sparing normal tissues. Founded in 2020 and based in Gothenburg, the company leverages deep expertise in cancer metabolism and DDR biology to develop first-in-class therapies. The one-carbon metabolism pathway has emerged as a critical vulnerability in various cancers and inflammatory conditions, and One-Carbon Therapeutics' platform holds potential for broad therapeutic applications. Currently in the pre-clinical stage, One-Carbon Therapeutics is advancing its lead candidate through in vitro and in vivo proof-of-concept studies. The company is focused on completing IND-enabling studies, including pharmacology, toxicology, and formulation development, with the goal of entering clinical trials within the next two years. Despite being an early-stage private company with no disclosed funding rounds, the scientific rationale and unmet medical need in DDR-targeted therapies position it as a potential candidate for partnership or further investment. Upcoming milestones include completion of key efficacy studies and initiation of regulatory interactions, which could significantly de-risk the program and attract strategic interest.

Upcoming Catalysts (preview)

• Q3 2026Completion of in vivo efficacy studies for lead candidate in oncology60% success
• Q1 2027Initiation of IND-enabling toxicology studies70% success
• H2 2026Strategic partnership or licensing agreement with a major pharma30% success